EUVIMEDEUVIMED entdecken
Open Access

Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma

Carla Saoud, Josephine K Dermawan, Aarti E Sharma, William Tap, Leonard H Wexler, Cristina R Antonescu iD

Genes, Chromosomes and Cancer · 2024-05 · 63 (5)

DOI: 10.1002/gcc.23238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 09.05.2024. Verfasst von Carla Saoud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Embryonal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cycle for Survival.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pleomorphic rhabdomyosarcoma (PRMS) is a rare and highly aggressive sarcoma, occurring mostly in the deep soft tissues of middle‐aged adults and showing a variable degree of skeletal muscle differentiation. The diagnosis is challenging as pathologic features overlap with embryonal rhabdomyosarcoma (ERMS), malignant Triton tumor, and other pleomorphic sarcomas. As recurrent genetic alterations underlying PRMS have not been described to date, ancillary molecular diagnostic testing is not useful in subclassification. Herein, we perform genomic profiling of a well‐characterized cohort of 14 PRMS, compared to a control group of 23 ERMS and other pleomorphic sarcomas (undifferentiated pleomorphic sarcoma and pleomorphic liposarcoma) using clinically validated DNA‐targeted Next generation sequencing (NGS) panels (MSK‐IMPACT). The PRMS cohort included eight males and six females, with a median age of 53 years (range 31–76 years). Despite similar tumor mutation burdens, the genomic landscape of PRMS, with a high frequency of TP53 (79%) and RB1 (43%) alterations, stood in stark contrast to ERMS, with 4% and 0%, respectively. CDKN2A deletions were more common in PRMS (43%), compared to ERMS (13%). In contrast, ERMS harbored somatic driver mutations in the RAS pathway and loss of function mutations in BCOR , which were absent in PRMS. Copy number variations in PRMS showed multiple chromosomal arm‐level changes, most commonly gains of chr17p and chr22q and loss of chr6q. Notably, gain of chr8, commonly seen in ERMS (61%) was conspicuously absent in PRMS. The genomic profiles of other pleomorphic sarcomas were overall analogous to PRMS, showing shared alterations in TP53 , RB1 , and CDKN2A . Overall survival and progression‐free survival of PRMS were significantly worse ( p < 0.0005) than that of ERMS. Our findings revealed that the molecular landscape of PRMS aligns with other adult pleomorphic sarcomas and is distinct from that of ERMS. Thus, NGS assays may be applied in select challenging cases toward a refined classification. Finally, our data corroborate the inclusion of PRMS in the therapeutic bracket of pleomorphic sarcomas, given that their clinical outcomes are comparable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhabdomyosarcoma, EmbryonalHumansMaleFemaleAdultMiddle AgedAgedRhabdomyosarcomaMutationHigh-Throughput Nucleotide SequencingGenomicsBiomarkers, TumorRetinoblastoma Binding ProteinsUbiquitin-Protein Ligases

Stichwörter der Autor:innen

embryonalgenomicspleomorphicrhabdomyosarcoma

Substanzen

Biomarkers, TumorRetinoblastoma Binding ProteinsRB1 protein, humanUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Cristina R Antonescu

Förderung

  • NCI NIH HHS
  • Cycle for Survival

Zitieren

APA

Saoud, C., Dermawan, J. K., Sharma, A. E., Tap, W., Wexler, L. H., & Antonescu, C. R. (2024). Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma. Genes, Chromosomes and Cancer, 63(5). https://doi.org/10.1002/gcc.23238

Vancouver

Saoud C, Dermawan JK, Sharma AE, Tap W, Wexler LH, Antonescu CR. Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma. Genes, Chromosomes and Cancer. 2024;63(5). doi:10.1002/gcc.23238

BibTeX
@article{Saoud2024,
  author = {Saoud, Carla and Dermawan, Josephine K and Sharma, Aarti E and Tap, William and Wexler, Leonard H and Antonescu, Cristina R},
  title = {Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma},
  journal = {Genes, Chromosomes and Cancer},
  year = {2024},
  volume = {63},
  number = {5},
  doi = {10.1002/gcc.23238}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche